Canada markets closed
  • S&P/TSX

    20,286.20
    +88.59 (+0.44%)
     
  • S&P 500

    3,941.48
    -32.27 (-0.81%)
     
  • DOW

    31,928.62
    +48.38 (+0.15%)
     
  • CAD/USD

    0.7802
    -0.0032 (-0.41%)
     
  • CRUDE OIL

    110.26
    -0.03 (-0.03%)
     
  • BTC-CAD

    37,814.64
    -34.95 (-0.09%)
     
  • CMC Crypto 200

    655.31
    -0.52 (-0.08%)
     
  • GOLD FUTURES

    1,865.50
    +17.70 (+0.96%)
     
  • RUSSELL 2000

    1,764.83
    -27.94 (-1.56%)
     
  • 10-Yr Bond

    2.7600
    -0.0990 (-3.46%)
     
  • NASDAQ futures

    11,810.75
    -224.50 (-1.87%)
     
  • VOLATILITY

    29.45
    +0.97 (+3.41%)
     
  • FTSE

    7,484.35
    -29.09 (-0.39%)
     
  • NIKKEI 225

    26,748.14
    -253.38 (-0.94%)
     
  • CAD/EUR

    0.7266
    -0.0056 (-0.76%)
     

Why Allakos Stock Plummeted 87.5% in the Last Month of 2021

·2 min read
Why Allakos Stock Plummeted 87.5% in the Last Month of 2021
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Allakos published phase 3 Enigma 2 and phase 2/3 Kryptos trial data on its lirentelimab monoclonal antibody as a treatment for eosinophilic gastrointestinal diseases (EGIDs), and the results shocked the market. Lirentelimab had shown promising results as a treatment for eosinophilic gastrointestinal diseases in its phase 2 trials, and the phase 3 data caught the market off guard. The crushing study results were followed by a series of downgrades from high-profile analysts.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting